A Phase 3 interventional study of Azilsartan medoxomil and Azilsartan medoxomil placebo in Hypertension, sponsored by Takeda. Completed at 15 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2016-12-19.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing azilsartan medoxomil in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. azilsartan medoxomil · Hypertension.
Among the 21 studies testing azilsartan medoxomil in Hypertension, this one is the 16th largest by enrollment, is the only one that started in 2014, is one of 17 in phase 3, and was the 20th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →1 of the 21 studies testing azilsartan medoxomil in Hypertension is open now, in 1 country. Recruiting first, the newest first:
Gedeon Richter Plc. · Sites in Russian Federation
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2014.
This study's enrollment of 328 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 566 across the 21 interventional studies. Of the 20 that completed or were terminated, 20 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 3 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
44 studies in Hypertension by Takeda: none open now, none under way, none of them phase 3. Of 43 finished, 34 (79%) have results posted.
Among the 44 studies in Hypertension by Takeda, this one is the 19th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2014, is one of 25 in phase 3, and was the 36th registered.
Takeda’s Hypertension studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing azilsartan medoxomil in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 44 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil versus placebo in Korean adults with essential hypertension.
The drug being tested in this study is called azilsartan medoxomil. Azilsartan medoxomil is being tested to treat Korean adults with hypertension. This study will look at changes in blood pressure in people who take azilsartan medoxomil.
The study will enroll approximately 325 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):
All participants will be asked to take two tablets at the same time each day throughout the study.
This multi-centre trial will be conducted in Korea. The overall time to participate in this study is 12 weeks. Participants will make 7 visits to the clinic, and will be contacted by telephone 7 days after last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Azilsartan medoxomil 40 mg, tablets, orally, once daily for 6 weeks.
Drug: Azilsartan medoxomil
Azilsartan medoxomil 80 mg, tablets, orally, once daily for 6 weeks.
Drug: Azilsartan medoxomil
Azilsartan medoxomil placebo-matching tablets, orally, once daily for 6 weeks.
Drug: Azilsartan medoxomil placebo
Azilsartan medoxomil tablets
Also known as: TAK-491
Azilsartan medoxomil placebo-matching tablets
Change From Baseline to Week 6 in Trough Clinic Sitting Systolic Blood Pressure (SBP)
The change in trough clinic sitting systolic blood pressure measured at week 6 relative to baseline. The trough is the average of the non-missing values of 3 serial trough sitting systolic blood pressure measurements. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 6 blood pressure was measured approximately 24 hours after the previous day's dose. An analysis of covariance (ANCOVA) model, with treatment group as a fixed effect and Baseline sitting clinic systolic blood pressure as a covariate was used for analysis.
Time frame: Baseline and Week 6
Change From Baseline to Week 6 in Trough Clinic Sitting Diastolic Blood Pressure (DBP)
The change in trough clinic sitting diastolic blood pressure measured at week 6 relative to baseline. The trough is the average of the non-missing values of 3 serial trough sitting diastolic blood pressure measurements. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 6 blood pressure was measured approximately 24 hours after the previous day's dose. An analysis of covariance (ANCOVA) model, with treatment group as a fixed effect and Baseline sitting clinic diastolic blood pressure as a covariate was used for analysis.
Time frame: Baseline and Week 6
Percentage of Participants Who Achieved a Clinic DBP Response at Week 6
Clinic DBP response is defined as clinic DBP \<90 mmHg and/or reduction of ≥10 mmHg from Baseline. DBP is the arithmetic mean of 3 serial diastolic blood pressure measurements.
Time frame: Baseline and Week 6
Percentage of Participants Who Achieved a Clinic SBP Response at Week 6
SBP response is defined as clinic SBP \<140 mmHg and/or reduction of ≥20 mmHg from Baseline. SBP is the arithmetic mean of 3 serial systolic blood pressure measurements.
Time frame: Baseline and Week 6
Percentage of Participants Who Achieved Both a Clinic DBP and SBP Response at Week 6
Percentage of participants who achieved both a clinic DBP and SBP response measured at week 6 defined as clinic DBP \<90 mmHg and/or reduction of ≥10 mmHg from Baseline AND clinic SBP \<140 mmHg and/or reduction of ≥20 mmHg from Baseline. DBP and SBP are based on the arithmetic mean of 3 serial blood pressure measurements.
Time frame: Baseline and Week 6
Participants took part in the study at 29 investigative sites in Korea from 12 July 2014 to 03 February 2016.
| Milestone | Placebo | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg |
|---|---|---|---|
| Started | 65 | 132 | 131 |
| Full analysis set (fas) | 65 | 132 | 130 |
| Safety analysis set (sas) | 65 | 132 | 130 |
| Completed | 57 | 122 | 120 |
| Not completed | 8 | 10 | 11 |
| Withdrew: Pretreatment event/adverse event | 1 | 3 | 2 |
| Withdrew: Major protocol deviation | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Voluntary withdrawal | 3 | 3 | 8 |
| Withdrew: Lack of efficacy | 3 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 2 | 1 |
The change in trough clinic sitting systolic blood pressure measured at week 6 relative to baseline. The trough is the average of the non-missing values of 3 serial trough sitting systolic blood pressure measurements. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 6 blood pressure was measured approximately 24 hours after the previous day's dose. An analysis of covariance (ANCOVA) model, with treatment group as a fixed effect and Baseline sitting clinic systolic blood pressure as a covariate was used for analysis.
| mmHg | Placebo | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg |
|---|---|---|---|
| Change From Baseline to Week 6 in Trough Clinic Sitting Systolic Blood Pressure (SBP) | -8.776 ± 2.0039 | -22.093 ± 1.4117 | -23.731 ± 1.4017 |
The change in trough clinic sitting diastolic blood pressure measured at week 6 relative to baseline. The trough is the average of the non-missing values of 3 serial trough sitting diastolic blood pressure measurements. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 6 blood pressure was measured approximately 24 hours after the previous day's dose. An analysis of covariance (ANCOVA) model, with treatment group as a fixed effect and Baseline sitting clinic diastolic blood pressure as a covariate was used for analysis.
| mmHg | Placebo | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg |
|---|---|---|---|
| Change From Baseline to Week 6 in Trough Clinic Sitting Diastolic Blood Pressure (DBP) | -2.6 ± 8.60 | -10.7 ± 10.12 | -11.6 ± 10.12 |
Clinic DBP response is defined as clinic DBP \<90 mmHg and/or reduction of ≥10 mmHg from Baseline. DBP is the arithmetic mean of 3 serial diastolic blood pressure measurements.
| percentage of participants | Placebo | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a Clinic DBP Response at Week 6 | 42.9 | 83.5 | 85.3 |
SBP response is defined as clinic SBP \<140 mmHg and/or reduction of ≥20 mmHg from Baseline. SBP is the arithmetic mean of 3 serial systolic blood pressure measurements.
| percentage of participants | Placebo | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a Clinic SBP Response at Week 6 | 38.1 | 63.0 | 65.9 |
Percentage of participants who achieved both a clinic DBP and SBP response measured at week 6 defined as clinic DBP \<90 mmHg and/or reduction of ≥10 mmHg from Baseline AND clinic SBP \<140 mmHg and/or reduction of ≥20 mmHg from Baseline. DBP and SBP are based on the arithmetic mean of 3 serial blood pressure measurements.
| percentage of participants | Placebo | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved Both a Clinic DBP and SBP Response at Week 6 | 25.4 | 62.2 | 65.9 |
Collected over Treatment-emergent adverse events: from the first dose of double-blind study drug to 14 days after the last dose (up to 66 days). Serious adverse events: from the first dose of double blind study drug to 30 days after the last dose (up to 82 days).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/65 (0%) | 7/65 (10.8%) |
| Azilsartan Medoxomil 40 mg | — | 0/132 (0%) | 8/132 (6.1%) |
| Azilsartan Medoxomil 80 mg | — | 2/130 (1.5%) | 14/130 (10.8%) |
| Event | Placebo | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg |
|---|---|---|---|
| Ligament sprainInjury, poisoning and procedural complications | 0/65 | 0/132 | 1/130 |
| Patella fractureInjury, poisoning and procedural complications | 0/65 | 0/132 | 1/130 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/65 | 0/132 | 1/130 |
| Tibia fractureInjury, poisoning and procedural complications | 0/65 | 0/132 | 1/130 |
| Event | Placebo | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg |
|---|---|---|---|
| DizzinessNervous system disorders | 0/65 | 3/132 | 7/130 |
| NasopharyngitisInfections and infestations | 3/65 | 2/132 | 4/130 |
| HeadacheNervous system disorders | 2/65 | 3/132 | 2/130 |
| DyspepsiaGastrointestinal disorders | 2/65 | 1/132 | 1/130 |
Safety Analysis Set (SAS) included all participants who received at least 1 dose of double-blind study drug and were randomized only once.
| Age, Continuous(years) | Placebo | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Total |
|---|---|---|---|---|
| Overall Study | 58.8 ± 10.21 | 59.8 ± 10.75 | 58.3 ± 11.57 | 59.0 ± 10.97 |
| Gender(Participants) | Placebo | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Total |
|---|---|---|---|---|
| Female | 14 | 37 | 37 | 88 |
| Male | 51 | 95 | 93 | 239 |
| Race/Ethnicity, Customized(participants) | Placebo | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Total |
|---|---|---|---|---|
| Asian | 65 | 132 | 130 | 327 |
| Region of Enrollment(participants) | Placebo | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Total |
|---|---|---|---|---|
| Korea, Republic Of | 65 | 132 | 130 | 327 |
| Height(cm) | Placebo | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Total |
|---|---|---|---|---|
| Mean | 166.1 ± 8.43 | 164.8 ± 9.09 | 165.6 ± 8.00 | 165.4 ± 8.53 |
| Weight(kg) | Placebo | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Total |
|---|---|---|---|---|
| Mean | 70.85 ± 9.892 | 70.97 ± 12.636 | 70.32 ± 13.070 | 70.69 ± 12.291 |
| Body Mass Index (BMI)(kg/m^2) | Placebo | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Total |
|---|---|---|---|---|
| Mean | 25.64 ± 2.653 | 26.02 ± 3.272 | 25.50 ± 3.460 | 25.74 ± 3.237 |
| Smoking Classification(participants) | Placebo | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Total |
|---|---|---|---|---|
| Never smoked | 29 | 71 | 65 | 165 |
| Current smoker | 12 | 22 | 26 | 60 |
| Ex-smoker | 24 | 39 | 39 | 102 |
3 further baseline measures are reported on the registry.
The record gives a start of Jul 2014, a primary completion of Jan 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azilsartan medoxomil